A comparison of the relative safety efficacy and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: The Quetiapine Experience with Safety and Tolerability (QUEST) study

Clinical Therapeutics

Volumn 23, Issue 11, 2001, Pages 1839-1854

  Mullen, Jamie ^a   Jibson, Michael D ^b   Sweitzer, Dennis ^a  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Atypical antipsychotic; Comparative study; Quetiapine; Risperidone; Schizophrenia; Tolerability

Indexed keywords

NEUROLEPTIC AGENT; QUETIAPINE; RISPERIDONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SOMNOLENCE; VERTIGO; XEROSTOMIA;

EID: 0035205669     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)89080-3     Document Type: Article

References (35)

1. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine quetiapine risperidone and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials
2. An overview of side effects caused by typical antipsychotics
3. Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia
4. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine
5. Evidence of clozapine's effectiveness in schizophrenia: A systematic review and meta-analysis of randomized trials
6. Adverse effects of the atypical antipsychotics
7. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
8. Risperidone in the treatment of schizophrenia
9. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national multi-centre double-blind parallel-group study versus haloperidol
10. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial
11. Olanzapine versus placebo: Results of a double-blind fixed-dose olanzapine trial
12. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
13. Adverse events related to olanzapine
14. Rapid release of antipsychotic drugs from dopamine D2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine
15. Quetiapine fumarate (Seroquel): A new atypical antipsychotic
16. ICI 204, 636 (Seroquel): A dibenothiazepine atypical antipsyschotic. Review of preclinical pharmacology and highlights of Phase II clinical trial
17. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
18. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo
19. Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204, 636)
20. Atypical antipsychotics and weight gain - A systematic review
21. The long-term effect of quetiapine ('Seroquel') monotherapy on weight in patients with schizophrenia
22. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study
23. Clozapine and risperidone treatment of psychosis in Parkinson's disease
24. An open comparison of clozapine and risperidone in treatment-resistant schizophrenia
25. Randomized double-blind controlled trial of risperidone versus clozapine in patients with chronic schizophrenia
26. Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: A prospective study
27. Comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder: A retrospective analysis
28. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
29. Clinical Global Impressions
30. The positive and negative syndrome scale (PANSS) for schizophrenia
31. Development of a rating scale for primary depressive illness
32. Why do schizophrenic patients refuse to take their drugs?